Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | HTR5A | P47898 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 4/20 | 0.33 |
| ▸ | ABHD6 | Q9BV23 | 3/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | BAZ2B | Q9UIF8 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19949264 | 0.82 | ESR2 (0.50) | ABHD6HDAC6 | |
| SCHEMBL30152216 | 0.82 | ESR2 (0.50) | ABHD6HDAC6 | |
| SCHEMBL29040808 | 0.78 | HDAC6 (0.40) | HTR5ARAB9AABHD6HDAC6BAZ2B | |
| SCHEMBL19948673 | 0.75 | ROCK1 (0.37) | BTK | |
| SCHEMBL19949181 | 0.75 | DPP4 (0.43) | BTKHTR5ARAB9AHDAC6NOTUM | |
| SCHEMBL2991719 | 0.74 | HCRTR1 (0.41) | RAB9AABHD6HDAC6NPC1ALDH1A1 | |
| SCHEMBL29118089 | 0.71 | ALDH1A1 (0.37) | HTR5ARAB9ANOTUMBAZ2BNPC1 | |
| SCHEMBL23458643 | 0.70 | ABHD6 (0.41) | ABHD6BAZ2BALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL28208067 | 0.70 | KMT2A (0.37) | RAB9ANOTUMNPC1ALDH1A1HPGD | |
| SCHEMBL31597954 | 0.70 | ABHD6 (0.38) | BTKHTR5ARAB9AABHD6HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542265-B2 | Pyrazolopyrimidine compounds and uses thereof | INCYTE CORPORATION (US) | 2023-01-03 | — | — | US | disclosed |
| US-20210371425-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2021-12-02 | — | — | US | disclosed |
| US-11014929-B2 | Pyrazolopyrimidine compounds and uses thereof | INCYTE CORPORATION (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200172545-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2020-06-04 | — | — | US | disclosed |
| US-20180072741-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172545-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, MAPKAPK5 | BTK 3973/4885HTR5A 3150/4885RAB9A 2168/4885 |
| US-20180072741-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PDK2 | BTK 4373/4885HTR5A 3009/4885RAB9A 2944/4885 |
| US-11014929-B2 | Pyrazolopyrimidine compounds and uses thereof | PDXK, PCK1, MAPKAPK5 | BTK 3973/4885HTR5A 3150/4885RAB9A 2168/4885 |
| US-11542265-B2 | Pyrazolopyrimidine compounds and uses thereof | PDXK, PCK1, PDK2 | BTK 4373/4885HTR5A 3009/4885RAB9A 2944/4885 |
| US-20210371425-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PDK2 | BTK 4373/4885HTR5A 3009/4885RAB9A 2944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.